1. Home
  2. ZNTL vs NEWT Comparison

ZNTL vs NEWT Comparison

Compare ZNTL & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZNTL
  • NEWT
  • Stock Information
  • Founded
  • ZNTL 2014
  • NEWT N/A
  • Country
  • ZNTL United States
  • NEWT United States
  • Employees
  • ZNTL N/A
  • NEWT N/A
  • Industry
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • NEWT Major Banks
  • Sector
  • ZNTL Health Care
  • NEWT Finance
  • Exchange
  • ZNTL Nasdaq
  • NEWT Nasdaq
  • Market Cap
  • ZNTL 300.4M
  • NEWT 338.4M
  • IPO Year
  • ZNTL 2020
  • NEWT N/A
  • Fundamental
  • Price
  • ZNTL $4.57
  • NEWT $14.70
  • Analyst Decision
  • ZNTL Buy
  • NEWT Buy
  • Analyst Count
  • ZNTL 7
  • NEWT 4
  • Target Price
  • ZNTL $13.14
  • NEWT $14.50
  • AVG Volume (30 Days)
  • ZNTL 3.0M
  • NEWT 164.3K
  • Earning Date
  • ZNTL 08-07-2024
  • NEWT 08-05-2024
  • Dividend Yield
  • ZNTL N/A
  • NEWT 5.17%
  • EPS Growth
  • ZNTL N/A
  • NEWT 7.14
  • EPS
  • ZNTL N/A
  • NEWT 1.80
  • Revenue
  • ZNTL $40,560,000.00
  • NEWT $199,910,000.00
  • Revenue This Year
  • ZNTL N/A
  • NEWT $34.20
  • Revenue Next Year
  • ZNTL N/A
  • NEWT $6.03
  • P/E Ratio
  • ZNTL N/A
  • NEWT $8.17
  • Revenue Growth
  • ZNTL N/A
  • NEWT 59.31
  • 52 Week Low
  • ZNTL $3.27
  • NEWT $10.07
  • 52 Week High
  • ZNTL $29.03
  • NEWT $19.36
  • Technical
  • Relative Strength Index (RSI)
  • ZNTL 36.44
  • NEWT 72.12
  • Support Level
  • ZNTL $3.83
  • NEWT $12.40
  • Resistance Level
  • ZNTL $4.27
  • NEWT $12.89
  • Average True Range (ATR)
  • ZNTL 0.40
  • NEWT 0.36
  • MACD
  • ZNTL 0.28
  • NEWT 0.23
  • Stochastic Oscillator
  • ZNTL 99.24
  • NEWT 99.29

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

About NEWT NewtekOne Inc.

NewtekOne Inc is a financial holding company engaged in providing financial solutions, It has developed a financial and technology-based business model that enables itself to acquire and process its clients in a very cost-effective manner. This capability is supported in large part by NewTracker, its patented prospect management technology software, that will allow NewtekOne clients to easily interact with NewtekOne subject matter experts in the areas of Banking, Lending, Payments, Technology, Payroll, and Insurance. It offers NewtekOne's clients a single online dashboard to access all of NewtekOne's business and financial solutions. It has four reportable segments Banking, Technology, NSBF, and Payments.

Share on Social Networks: